RT Journal Article
SR Electronic
T1 Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.07.20139261
DO 10.1101/2020.08.07.20139261
A1 Mary Ann A. DeMichele-Sweet
A1 Lambertus Klei
A1 Byron Creese
A1 Elise A. Weamer
A1 Lora McClain
A1 Rebecca Sims
A1 Isabel Hernandez
A1 Sonia Moreno-Grau
A1 Lluís Tárraga
A1 Mercè Boada
A1 Emilio Alarcón-Martín
A1 Sergi Valero
A1 NIA-LOAD Family Based Study Consortium
A1 Alzheimer’s Disease Genetics Consortium (ADGC)
A1 Yushi Liu
A1 Basavaraj Hooli
A1 Dag Aarsland
A1 Geir Selbaek
A1 Sverre Bergh
A1 Arvid Rongve
A1 Ingvild Saltvedt
A1 Håvard K. Skjellegrind
A1 Bo Engdahl
A1 Eystein Stordal
A1 Ole A. Andreassen
A1 Srdjan Djurovic
A1 Lavinia Athanasiu
A1 Davide Seripa
A1 Barbara Borroni
A1 Diego Albani
A1 Gianluigi Forloni
A1 Patrizia Meccoci
A1 Alessandro Serretti
A1 Diana De Ronchi
A1 Antonis Politis
A1 Giulia Paroni
A1 AddNeuroMed Consortium
A1 Julie Williams
A1 Richard Mayeux
A1 Tatiana Foroud
A1 Agustin Ruiz
A1 Clive Ballard
A1 Oscar L. Lopez
A1 M. Ilyas Kamboh
A1 Bernie Devlin
A1 Robert A. Sweet
YR 2020
UL http://medrxiv.org/content/early/2020/08/11/2020.08.07.20139261.abstract
AB Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD with psychosis, AD+P), affecting ~ 40% to 60% of individuals with AD. AD+P identifies a subgroup of AD patients with poor outcomes. The strongest clinical predictor of AD+P is a greater degree of cognitive impairment than in AD subjects without psychosis (AD-P). Other frequently replicated correlates of AD+P include elevated depressive symptoms. Although the estimated heritability of psychosis in AD is 61%, the underlying genetic sources of this risk are not known. We report a genome-wide meta-analysis of 12,317 AD subjects, with and without psychosis. Results showed common genetic variation accounted for a significant portion of heritability. Two loci, one in the gene ENPP6 (best SNP rs9994623, O.R. (95%CI) 1.16 (1.10, 1.22), p=1.26×10-8) and one spanning the 3’-UTR of an alternatively spliced transcript of SUMF1 (best SNP rs201109606, O.R. 0.65 (0.56-0.76), p=3.24×10-8), had genome-wide significant associations with the risk of psychosis in AD. Psychosis risk in AD demonstrated negative genetic correlations with cognitive and educational attainment and positive genetic correlation with depressive symptoms. We had previously observed a negative genetic correlation with schizophrenia, instead we now found a stronger negative correlation with the related phenotype of bipolar disorder. Psychosis risk in AD was not genetically correlated with AD or other neurodegenerative diseases. These findings provide the first unbiased identification of the association of psychosis in AD with common genetic variation and provide insights into its genetic architecture. Study of the genetic mechanisms underlying the associations of loci in ENPP6 and SUMF1 with psychosis in AD are warranted.Competing Interest StatementYushi Liu and Basavaraj Hooli are currently employed by and holding stock in Eli Lilly and Company. Dr. Clive Ballard reports grants and personal fees from Acadia pharmaceutical company, grants and personal fees from Lundbeck, personal fees from Roche, personal fees from Otsuka, personal fees from Biogen, personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from AARP, grants and personal fees from Synexus, personal fees from Exciva, outside the submitted work. Dr. Oscar Lopez served as a consultant for Grifols, Inc. Dr Saltvedt has been investigator in the drug trial Boehringer-Ingelheim 1346.0023 Ole A. Andreassen: Consultant to HEALTHLYTIX, speaker honoraria from Lundbeck. Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT00594568 https://clinicaltrials.gov/ct2/show/NCT00762411 https://clinicaltrials.gov/ct2/show/NCT00905372 https://clinicaltrials.gov/ct2/show/NCT00904683 https://clinicaltrials.gov/ct2/show/NCT00051909 https://clinicaltrials.gov/ct2/show/NCT00843518 https://clinicaltrials.gov/ct2/show/NCT00191009 https://clinicaltrials.gov/ct2/show/NCT01900665 Funding StatementRAS: AG027224 and MH116046 BD: MH057881 MIK: AG030653 and AG041718 OLL: AG066468 MB and AR: European Union/EFPIA Innovative Medicines Initiative Joint Undertaking ADAPTED-Grant No 115975, MOPEAD-Grant No. 115985, PI13/02434, I16/01861, PI17/01474, PI19/01301, and CIBERNED grant 2019/08 The genotyping service to generate GRatACE GWAS data: grant PT17/0019 of the PE I+D+i 2013-2016, funded by ISCIII and ERDF National Centralized Repository for Alzheimers Disease and Related Dementias (NCRAD): U24 AG021886 The NACC database: NIA/NIH Grant U01 AG016976 The Alzheimers Disease Genetics Consortium (ADGC): NIA grants U01AG032984 and RC2AG036528 National Institute on Aging Alzheimers Disease Data Storage Site (NIAGADS): U24-AG041689-01 NEXGENS: National Institute on Aging of the National Institutes of Health R01AG067015 AddNeuroMed: EU FP6 program as part of InnoMed NorCog: South-Eastern Norway Regional Health Authority and Norwegian National Advisory Unit on Ageing and Health HMS: the Norwegian Institute of Public Health, the Norwegian University of Science and Technology (NTNU), Nord-Tr&oslashndelag Hospital Trust, and Innlandet Hospital Trust REDIC-NH: Age-Related Functional Decline and Disease, Innlandet Hospital Trust, and the Norwegian Health Directorate NIMH: U01 MH46281, U01 MH46290, U01 MH46373 Ole A. Andreassen: Research Council of Norway #223273 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of all clinical data and genetic samples were approved by the Institutional Review Board or Medical Ethics Committee, as appropriate, for each source programAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be submitted to NIAGADS (https://www.niagads.org) upon acceptance of peer-reviewed manuscript. http://csg.sph.umich.edu/abecasis/metal/index.html http://www.compgen.pitt.edu/GemTools/GemTools.htm https://www.cog-genomics.org/plink2/ https://ftp.ncbi.nih.gov/snp/redesign/latest_release/VCF/ http://ldsc.broadinstitute.org/ldhub/ https://imputation.sanger.ac.uk https://www.med.unc.edu/pgc/ https://www.well.ox.ac.uk/~wrayner/tools/ https://www.synapse.org/#!Synapse:syn16984815